AAX Biotech Awarded AbbVie Scandinavia Golden Ticket
AAX Biotech is happy to announce its selection as the winner of the AbbVie Scandinavia Golden Ticket. This award grants AAX Biotech access to the SmiLe Incubator's collection of resources, including laboratory and office space, as well as mentoring and business development support, enhancing its efforts in developing antibody-based therapeutics.
AAX Biotech is a Swedish startup biotech company aiming to solve unmet needs in developing next-generation antibody therapeutics. The company’s two unique and patentable technologies, Seqitope™ and Opti-mAb™, improve the performance and developability of antibody-based therapeutics and offer a unique solution in a rapidly growing market.
As part of the Golden Ticket program, AAX Biotech will gain one year of access to laboratory space, research and office facilities, and services provided by SmiLe Incubator in Lund. Additionally, the company will benefit from mentorship and business coaching from SmiLe, tailored support from AbbVie's international researchers and mentors, and exclusive networking opportunities, paving the way for future collaborations.
Maria Knudsen, CEO of AAX Biotech, expresses her gratitude and excitement, "Being awarded the AbbVie Scandinavia Golden Ticket is a tremendous honor and validation of our innovative approach to biotechnology. This recognition not only fuels our commitment to pushing the boundaries of biotech but also significantly accelerates our mission to meet the unmet medical needs of today. We are eager to leverage this opportunity to enhance patient treatment methods and improve quality of life."
“It is with great pleasure that we announce AAX Biotech as the winner today, a decision made with considerable care. We believe AAX Biotech presents a unique and promising solution with the potential to deliver value to an even broader patient population in the future," says Matthew Iles, General Manager Scandinavia at AbbVie.
”We are very pleased to see AAX Biotech as the winner of the Golden Ticket. We look forward to being part of their journey in shaping the future of antibody-based therapeutics and supporting them with our expertise, our state-of-the-art lab infrastructure and our networks for the upcoming year,” says Ebba Fåhraeus, CEO of SmiLe.
The AbbVie Scandinavia Golden Ticket program aims to assist promising startups in commercializing their innovative drug research, focusing on key areas such as oncology, neuroscience, immunology, ophthalmology, and aesthetics. AAX Biotech was chosen from a highly competitive group of applicants, emphasizing the company's potential to significantly impact the future of medicine with its unique platform technologies.
For more information, please contact:
Maria Lisa Knudsen, CEO
+46 72 939 5018
maria.knudsen@aaxbiotech.com
About AAX Biotech AB
AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics. The company offers two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. AAX Biotech is founded by experts from Karolinska Institutet in Stockholm, Sweden. Visit aaxbiotech.com to learn more and follow AAX Biotech on LinkedIn.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care. For more information about AbbVie, please visit us at www.abbvie.se, Facebook@AbbVieSverige, and X @abbvie_se.
About SmiLe
SmiLe is a venture hub located in Lund, Sweden, specializing in accelerating the growth of innovative life science ventures. We offer tailored programs and educational courses, expert coaching, state-of-the-art labs, as well as access to international industry networks and funding opportunities. Since the start, our incubator program has supported more than 110 entrepreneurs and together they have attracted more than EUR 841 million in venture capital. To date, 21 of SmiLe´s companies have launched an IPO. SmiLe has been recognized as one of Europe’s Leading Startup-hubs 2024 by Financial Times and Statista.
